Chris Garabedian is a biopharma executive with over 25 years of industry experience and a proven track record of success, including leadership roles at two of the most successful biopharma companies of the last 20 years, Celgene and Gilead. As former CEO of Sarepta Therapeutics, Mr. Garabedian orchestrated a turnaround of a 30-year old struggling company into a highly-valued leader in genetic-based technology and rare disease drug development. He is currently Chairman of Xontogeny LLC, a biotechnology incubator where he serves as co- founder, investor and advisor to several early-stage life sciences companies.
As CEO of Sarepta from 2011 to 2015, Mr. Garabedian advanced the company R&D from one drug in early clinical development to six drugs in mid- to late-stage development, including a lead program in Duchenne Muscular Dystrophy (DMD) that led to FDA approval under the Accelerated Approval pathway in September 2016. He also scaled-up manufacturing capabilities to commercial scale. Mr. Garabedian was nominated for Best CEO of the Year (The Street, 2012) and named one of the top 50 Orphan Drug Thought Leaders (WODC, 2014), while establishing a reputation as a strong patient advocate. He was featured in the acclaimed book, The Right To Try (Darcy Olsen, 2016), where his interactions with the DMD patient community and his industry perspective on early access to drugs were detailed.
Prior to his CEO role at Sarepta, Mr. Garabedian served as Vice President of Corporate Strategy for Celgene from 2007 to 2010 where he was responsible for strategic planning, M&A, portfolio review and other strategic initiatives. Prior to Celgene, Mr. Garabedian worked at Gilead Sciences from 1997 to 2005 where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. He developed expertise in managing corporate development initiatives including portfolio review and strategic planning, M&A/business development, and leading four global product launches. Mr. Garabedian also held various commercial development positions at COR Therapeutics (acquired by Millennium) from 1998 to 1999 and at Abbott Laboratories (now Abbvie) from 1994 to 1997. He started his biopharmaceutical career as a consultant to the industry from 1991 to 1994.
Mr. Garabedian is a frequent speaker across a variety of topics at industry conferences. Additionally, he serves as a Senior Advisor to the Boston Consulting Group, and as a member of faculty for the GLG Institute. He is also on the Board of Directors for MassBio and on the Advisory Council for the Keck Graduate Institute of Applied Life Sciences.